- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
According to our latest study, the global Multiparametric In-vitro Cardiotoxicity Testing market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Multiparametric In-vitro Cardiotoxicity Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type of Assay and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Multiparametric In-vitro Cardiotoxicity Testing market size and forecasts, in consumption value ($ Million), 2018-2029
Global Multiparametric In-vitro Cardiotoxicity Testing market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Multiparametric In-vitro Cardiotoxicity Testing market size and forecasts, by Type of Assay and by Application, in consumption value ($ Million), 2018-2029
Global Multiparametric In-vitro Cardiotoxicity Testing market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Multiparametric In-vitro Cardiotoxicity Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Multiparametric In-vitro Cardiotoxicity Testing market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Creative Bioarray, Agilent Technologies, Inc., Hemogenix Inc., Merck KGaA and Molecular Devices, LLC., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Multiparametric In-vitro Cardiotoxicity Testing market is split by Type of Assay and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type of Assay and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type of Assay
Calcium Transient Assay
Cardiac Marker Detection
hERG Assay
Multi-ion Channel Assay
Others
Market segment by Application
Contract Research Organizations (CROs)
Pharmaceutical and Biotech Companies
Others
Market segment by players, this report covers
Creative Bioarray
Agilent Technologies, Inc.
Hemogenix Inc.
Merck KGaA
Molecular Devices, LLC.
Miltenyi Biotec
FUJIFILM Cellular Dynamics
Enzo Life Sciences, Inc.
Axol Bioscience Ltd.
emka TECHNOLOGIES
Eurofins Discovery
Stemina Biomarker Discovery, Inc.
Evotec
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Multiparametric In-vitro Cardiotoxicity Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Multiparametric In-vitro Cardiotoxicity Testing, with revenue, gross margin and global market share of Multiparametric In-vitro Cardiotoxicity Testing from 2018 to 2023.
Chapter 3, the Multiparametric In-vitro Cardiotoxicity Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type of Assay and application, with consumption value and growth rate by Type of Assay, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Multiparametric In-vitro Cardiotoxicity Testing market forecast, by regions, type of assay and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Multiparametric In-vitro Cardiotoxicity Testing.
Chapter 13, to describe Multiparametric In-vitro Cardiotoxicity Testing research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Multiparametric In-vitro Cardiotoxicity Testing
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Multiparametric In-vitro Cardiotoxicity Testing by Type of Assay
1.3.1 Overview: Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Type of Assay: 2018 Versus 2022 Versus 2029
1.3.2 Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Type of Assay in 2022
1.3.3 Calcium Transient Assay
1.3.4 Cardiac Marker Detection
1.3.5 hERG Assay
1.3.6 Multi-ion Channel Assay
1.3.7 Others
1.4 Global Multiparametric In-vitro Cardiotoxicity Testing Market by Application
1.4.1 Overview: Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Contract Research Organizations (CROs)
1.4.3 Pharmaceutical and Biotech Companies
1.4.4 Others
1.5 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size & Forecast
1.6 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast by Region
1.6.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region, (2018-2029)
1.6.3 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size and Prospect (2018-2029)
1.6.4 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size and Prospect (2018-2029)
1.6.6 South America Multiparametric In-vitro Cardiotoxicity Testing Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Creative Bioarray
2.1.1 Creative Bioarray Details
2.1.2 Creative Bioarray Major Business
2.1.3 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.1.4 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Creative Bioarray Recent Developments and Future Plans
2.2 Agilent Technologies, Inc.
2.2.1 Agilent Technologies, Inc. Details
2.2.2 Agilent Technologies, Inc. Major Business
2.2.3 Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.2.4 Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Agilent Technologies, Inc. Recent Developments and Future Plans
2.3 Hemogenix Inc.
2.3.1 Hemogenix Inc. Details
2.3.2 Hemogenix Inc. Major Business
2.3.3 Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.3.4 Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Hemogenix Inc. Recent Developments and Future Plans
2.4 Merck KGaA
2.4.1 Merck KGaA Details
2.4.2 Merck KGaA Major Business
2.4.3 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.4.4 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck KGaA Recent Developments and Future Plans
2.5 Molecular Devices, LLC.
2.5.1 Molecular Devices, LLC. Details
2.5.2 Molecular Devices, LLC. Major Business
2.5.3 Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.5.4 Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Molecular Devices, LLC. Recent Developments and Future Plans
2.6 Miltenyi Biotec
2.6.1 Miltenyi Biotec Details
2.6.2 Miltenyi Biotec Major Business
2.6.3 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.6.4 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Miltenyi Biotec Recent Developments and Future Plans
2.7 FUJIFILM Cellular Dynamics
2.7.1 FUJIFILM Cellular Dynamics Details
2.7.2 FUJIFILM Cellular Dynamics Major Business
2.7.3 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.7.4 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 FUJIFILM Cellular Dynamics Recent Developments and Future Plans
2.8 Enzo Life Sciences, Inc.
2.8.1 Enzo Life Sciences, Inc. Details
2.8.2 Enzo Life Sciences, Inc. Major Business
2.8.3 Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.8.4 Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Enzo Life Sciences, Inc. Recent Developments and Future Plans
2.9 Axol Bioscience Ltd.
2.9.1 Axol Bioscience Ltd. Details
2.9.2 Axol Bioscience Ltd. Major Business
2.9.3 Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.9.4 Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Axol Bioscience Ltd. Recent Developments and Future Plans
2.10 emka TECHNOLOGIES
2.10.1 emka TECHNOLOGIES Details
2.10.2 emka TECHNOLOGIES Major Business
2.10.3 emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.10.4 emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 emka TECHNOLOGIES Recent Developments and Future Plans
2.11 Eurofins Discovery
2.11.1 Eurofins Discovery Details
2.11.2 Eurofins Discovery Major Business
2.11.3 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.11.4 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Eurofins Discovery Recent Developments and Future Plans
2.12 Stemina Biomarker Discovery, Inc.
2.12.1 Stemina Biomarker Discovery, Inc. Details
2.12.2 Stemina Biomarker Discovery, Inc. Major Business
2.12.3 Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.12.4 Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Stemina Biomarker Discovery, Inc. Recent Developments and Future Plans
2.13 Evotec
2.13.1 Evotec Details
2.13.2 Evotec Major Business
2.13.3 Evotec Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
2.13.4 Evotec Multiparametric In-vitro Cardiotoxicity Testing Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Evotec Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Multiparametric In-vitro Cardiotoxicity Testing Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Multiparametric In-vitro Cardiotoxicity Testing by Company Revenue
3.2.2 Top 3 Multiparametric In-vitro Cardiotoxicity Testing Players Market Share in 2022
3.2.3 Top 6 Multiparametric In-vitro Cardiotoxicity Testing Players Market Share in 2022
3.3 Multiparametric In-vitro Cardiotoxicity Testing Market: Overall Company Footprint Analysis
3.3.1 Multiparametric In-vitro Cardiotoxicity Testing Market: Region Footprint
3.3.2 Multiparametric In-vitro Cardiotoxicity Testing Market: Company Product Type Footprint
3.3.3 Multiparametric In-vitro Cardiotoxicity Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type of Assay
4.1 Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value and Market Share by Type of Assay (2018-2023)
4.2 Global Multiparametric In-vitro Cardiotoxicity Testing Market Forecast by Type of Assay (2024-2029)
5 Market Size Segment by Application
5.1 Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Application (2018-2023)
5.2 Global Multiparametric In-vitro Cardiotoxicity Testing Market Forecast by Application (2024-2029)
6 North America
6.1 North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2029)
6.2 North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2029)
6.3 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country
6.3.1 North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2029)
6.3.2 United States Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
6.3.3 Canada Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
6.3.4 Mexico Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2029)
7.2 Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2029)
7.3 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country
7.3.1 Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2029)
7.3.2 Germany Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
7.3.3 France Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
7.3.5 Russia Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
7.3.6 Italy Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2029)
8.2 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region
8.3.1 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Region (2018-2029)
8.3.2 China Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
8.3.3 Japan Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
8.3.4 South Korea Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
8.3.5 India Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
8.3.7 Australia Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
9 South America
9.1 South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2029)
9.2 South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2029)
9.3 South America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country
9.3.1 South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2029)
9.3.2 Brazil Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
9.3.3 Argentina Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2029)
10.2 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country
10.3.1 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2029)
10.3.2 Turkey Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
10.3.4 UAE Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Multiparametric In-vitro Cardiotoxicity Testing Market Drivers
11.2 Multiparametric In-vitro Cardiotoxicity Testing Market Restraints
11.3 Multiparametric In-vitro Cardiotoxicity Testing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Multiparametric In-vitro Cardiotoxicity Testing Industry Chain
12.2 Multiparametric In-vitro Cardiotoxicity Testing Upstream Analysis
12.3 Multiparametric In-vitro Cardiotoxicity Testing Midstream Analysis
12.4 Multiparametric In-vitro Cardiotoxicity Testing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay, (USD Million), 2018 & 2022 & 2029
Table 2. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Creative Bioarray Company Information, Head Office, and Major Competitors
Table 6. Creative Bioarray Major Business
Table 7. Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 8. Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Creative Bioarray Recent Developments and Future Plans
Table 10. Agilent Technologies, Inc. Company Information, Head Office, and Major Competitors
Table 11. Agilent Technologies, Inc. Major Business
Table 12. Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 13. Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Agilent Technologies, Inc. Recent Developments and Future Plans
Table 15. Hemogenix Inc. Company Information, Head Office, and Major Competitors
Table 16. Hemogenix Inc. Major Business
Table 17. Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 18. Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Hemogenix Inc. Recent Developments and Future Plans
Table 20. Merck KGaA Company Information, Head Office, and Major Competitors
Table 21. Merck KGaA Major Business
Table 22. Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 23. Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Merck KGaA Recent Developments and Future Plans
Table 25. Molecular Devices, LLC. Company Information, Head Office, and Major Competitors
Table 26. Molecular Devices, LLC. Major Business
Table 27. Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 28. Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Molecular Devices, LLC. Recent Developments and Future Plans
Table 30. Miltenyi Biotec Company Information, Head Office, and Major Competitors
Table 31. Miltenyi Biotec Major Business
Table 32. Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 33. Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Miltenyi Biotec Recent Developments and Future Plans
Table 35. FUJIFILM Cellular Dynamics Company Information, Head Office, and Major Competitors
Table 36. FUJIFILM Cellular Dynamics Major Business
Table 37. FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 38. FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. FUJIFILM Cellular Dynamics Recent Developments and Future Plans
Table 40. Enzo Life Sciences, Inc. Company Information, Head Office, and Major Competitors
Table 41. Enzo Life Sciences, Inc. Major Business
Table 42. Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 43. Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Enzo Life Sciences, Inc. Recent Developments and Future Plans
Table 45. Axol Bioscience Ltd. Company Information, Head Office, and Major Competitors
Table 46. Axol Bioscience Ltd. Major Business
Table 47. Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 48. Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Axol Bioscience Ltd. Recent Developments and Future Plans
Table 50. emka TECHNOLOGIES Company Information, Head Office, and Major Competitors
Table 51. emka TECHNOLOGIES Major Business
Table 52. emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 53. emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. emka TECHNOLOGIES Recent Developments and Future Plans
Table 55. Eurofins Discovery Company Information, Head Office, and Major Competitors
Table 56. Eurofins Discovery Major Business
Table 57. Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 58. Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Eurofins Discovery Recent Developments and Future Plans
Table 60. Stemina Biomarker Discovery, Inc. Company Information, Head Office, and Major Competitors
Table 61. Stemina Biomarker Discovery, Inc. Major Business
Table 62. Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 63. Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Stemina Biomarker Discovery, Inc. Recent Developments and Future Plans
Table 65. Evotec Company Information, Head Office, and Major Competitors
Table 66. Evotec Major Business
Table 67. Evotec Multiparametric In-vitro Cardiotoxicity Testing Product and Solutions
Table 68. Evotec Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Evotec Recent Developments and Future Plans
Table 70. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue (USD Million) by Players (2018-2023)
Table 71. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Share by Players (2018-2023)
Table 72. Breakdown of Multiparametric In-vitro Cardiotoxicity Testing by Company Type (Tier 1, Tier 2, and Tier 3)
Table 73. Market Position of Players in Multiparametric In-vitro Cardiotoxicity Testing, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 74. Head Office of Key Multiparametric In-vitro Cardiotoxicity Testing Players
Table 75. Multiparametric In-vitro Cardiotoxicity Testing Market: Company Product Type Footprint
Table 76. Multiparametric In-vitro Cardiotoxicity Testing Market: Company Product Application Footprint
Table 77. Multiparametric In-vitro Cardiotoxicity Testing New Market Entrants and Barriers to Market Entry
Table 78. Multiparametric In-vitro Cardiotoxicity Testing Mergers, Acquisition, Agreements, and Collaborations
Table 79. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (USD Million) by Type of Assay (2018-2023)
Table 80. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Share by Type of Assay (2018-2023)
Table 81. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Forecast by Type of Assay (2024-2029)
Table 82. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2023)
Table 83. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Forecast by Application (2024-2029)
Table 84. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2023) & (USD Million)
Table 85. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2024-2029) & (USD Million)
Table 86. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 87. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 88. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 89. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 90. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2023) & (USD Million)
Table 91. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2024-2029) & (USD Million)
Table 92. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 93. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 94. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2023) & (USD Million)
Table 97. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2024-2029) & (USD Million)
Table 98. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 99. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 100. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 101. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Region (2024-2029) & (USD Million)
Table 102. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2023) & (USD Million)
Table 103. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2024-2029) & (USD Million)
Table 104. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 105. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 106. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 107. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2018-2023) & (USD Million)
Table 109. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay (2024-2029) & (USD Million)
Table 110. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 111. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 112. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 113. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 114. Multiparametric In-vitro Cardiotoxicity Testing Raw Material
Table 115. Key Suppliers of Multiparametric In-vitro Cardiotoxicity Testing Raw Materials
List of Figures
Figure 1. Multiparametric In-vitro Cardiotoxicity Testing Picture
Figure 2. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Type of Assay in 2022
Figure 4. Calcium Transient Assay
Figure 5. Cardiac Marker Detection
Figure 6. hERG Assay
Figure 7. Multi-ion Channel Assay
Figure 8. Others
Figure 9. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value by Type of Assay, (USD Million), 2018 & 2022 & 2029
Figure 10. Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Application in 2022
Figure 11. Contract Research Organizations (CROs) Picture
Figure 12. Pharmaceutical and Biotech Companies Picture
Figure 13. Others Picture
Figure 14. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Region in 2022
Figure 19. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Share by Players in 2022
Figure 25. Multiparametric In-vitro Cardiotoxicity Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Multiparametric In-vitro Cardiotoxicity Testing Market Share in 2022
Figure 27. Global Top 6 Players Multiparametric In-vitro Cardiotoxicity Testing Market Share in 2022
Figure 28. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Share by Type of Assay (2018-2023)
Figure 29. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share Forecast by Type of Assay (2024-2029)
Figure 30. Global Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Share by Application (2018-2023)
Figure 31. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share Forecast by Application (2024-2029)
Figure 32. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Type of Assay (2018-2029)
Figure 33. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Type of Assay (2018-2029)
Figure 39. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 42. France Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Type of Assay (2018-2029)
Figure 47. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Region (2018-2029)
Figure 49. China Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 52. India Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Type of Assay (2018-2029)
Figure 56. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Type of Assay (2018-2029)
Figure 61. Middle East and Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Multiparametric In-vitro Cardiotoxicity Testing Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Multiparametric In-vitro Cardiotoxicity Testing Consumption Value (2018-2029) & (USD Million)
Figure 66. Multiparametric In-vitro Cardiotoxicity Testing Market Drivers
Figure 67. Multiparametric In-vitro Cardiotoxicity Testing Market Restraints
Figure 68. Multiparametric In-vitro Cardiotoxicity Testing Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Multiparametric In-vitro Cardiotoxicity Testing in 2022
Figure 71. Manufacturing Process Analysis of Multiparametric In-vitro Cardiotoxicity Testing
Figure 72. Multiparametric In-vitro Cardiotoxicity Testing Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
